Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs

Biological Psychiatry

Volumn 67, Issue 3, 2010, Pages 255-262

  Andreasen, Nancy C ^a   Pressler, Marcus ^a   Nopoulos, Peg ^a   Miller, Del ^a   Ho, Beng Choon ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Antipsychotics; chlorpromazine equivalents; dose years; haloperidol equivalents; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE CALCULATION; PRIORITY JOURNAL;

ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HALOPERIDOL; HUMANS; LINEAR MODELS; MENTAL DISORDERS; QUESTIONNAIRES; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 73549110068     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2009.08.040     Document Type: Article

References (18)

1. Andreasen N.C., Flaum M., and Arndt S. The comprehensive assessment of symptoms and history (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 49 (1992) 615-623
2. Miller D.D., Flaum M., Nopoulos P., Arndt S., and Andreasen N.C. The concept of dose years: A reliable method for calculating lifetime psychotropic drug exposure. Schizophr Res 15 (1995) 159
3. Davis J.M. Dose equivalence of the antipsychotic drugs. J Psychiatr Res 11 (1974) 65-69
4. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64 (2003) 663-667
5. Kane J.M., Leucht S., Carpenter D., and Docherty J.P. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. J Clin Psychiatry 64 suppl 12 (2003) 5-19
6. Kane J.M., Leucht S., Carpenter D., and Docherty J.P. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 64 suppl 12 (2003) 2-97 Quiz: 98-100
7. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
8. Corson P.W., Nopoulos P., Miller D.D., Arndt S., and Andreasen N.C. Change in basal ganglia volume over 2 years in patients with schizophrenia: Typical versus atypical neuroleptics. Am J Psychiatry 156 (1999) 1200-1204
9. Davis J.M., and Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 24 (2004) 192-208
10. Keck Jr. P., Buffenstein A., Ferguson J., Feighner J., Jaffe W., Harrigan E.P., et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial. Psychopharmacology 140 (1998) 173-184
11. Mamo D., Kapur S., Shammi C.M., Papatheodorou G., Mann S., Therrien F., et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161 (2004) 818-825
12. Arvanitis L.A., and Miller B.G. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42 (1997) 233-246
13. Small J.G., Hirsch S.R., Arvanitis L.A., Miller B.G., and Link C.G. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 54 (1997) 549-557
14. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., and Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49 (1992) 538-544
15. Farde L., Wiesel F.A., Halldin C., and Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45 (1988) 71-76
16. Tauscher J., Hussain T., Agid O., Verhoeff N.P., Wilson A.A., Houle S., et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: Differentiation from other atypical antipsychotics. Am J Psychiatry 161 (2004) 1620-1625
17. Tauscher J., and Kapur S. Choosing the right dose of antipsychotics in schizophrenia: Lessons from neuroimaging studies. CNS Drugs 15 (2001) 671-678
18. Seeman P. Atypical antipsychotics: Mechanism of action. Focus 2 (2004) 48-58